Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04880031 · ClinicalTrials.gov registry record · Phase 2
A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an Extension
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 231
- Enrollment target
NCT04880031 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 231 participants.
The verdict
NCT04880031, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 231 participants
- Enrollment target
Study Summary
This is a randomized, blinded, placebo-controlled study of Efimosfermin in obese participants at risk for, or with biopsy-confirmed, nonalcoholic steatohepatitis (NASH), with a single arm open-label extension. It includes Parts A, B, C and D.
Interventions
- DRUG Placebo
- DRUG Efimosfermin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 231 participants |
| Start Date | 2021-09-30 |
| Est. Completion | 2025-10-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04880031
The ClinicalTrials.gov registry entry for NCT04880031 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 231 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04880031 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04880031 about?
NCT04880031 is a clinical study titled "A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an Extension". This is a randomized, blinded, placebo-controlled study of Efimosfermin in obese participants at risk for, or with biopsy-confirmed, nonalcoholic steatohepatitis (NASH), with a single arm open-label extension. It includes Parts A, B, C and D.
What is the current status of trial NCT04880031?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 231 participants. The study started on 2021-09-30. Estimated completion is 2025-10-27.
What interventions are being tested in trial NCT04880031?
The interventions under investigation include: Placebo (DRUG), Efimosfermin (DRUG).
Who is sponsoring clinical trial NCT04880031?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.